Market Overview:
The global high-throughput screening market size reached US$ 25.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 49.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032.
Report Attribute
|
Key Statistics
|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
US$ 25.2 Billion |
Market Forecast in 2032
|
US$ 49.0 Billion |
Market Growth Rate (2024-2032) |
7.5% |
High-throughput screening (HTS) is a drug discovery process that allows automated testing of different chemical and biological compounds for a biological target. It relies on liquid handling devices, robotics, plate readers, and dedicated software for instrumentation control and data processing. It enables sample minimization, high-speed automation, and single-molecule and low background signals detection. HTS helps scientists generate and utilize large datasets for answering complex biological questions. As a result, it finds wide applications in pharmaceuticals, biotech and academic institutes, target validation, and the identification of genes that modulate a particular biological pathway.
High-throughput Screening Market Trends:
At present, there is a rise in the utilization of HTS for minimizing the time required for manufacturing a drug. This, along with the development of new medicines for treating various life-threatening diseases, represents one of the key factors driving the market. Moreover, governments of several countries are investing in new technologies, such as a microplate-free approach, clustered regularly interspaced short palindromic repeats (CRISPR) and RNA interference (RNAi), and artificial intelligence (AI) and machine learning (ML). This, coupled with the increasing application of automation in HTS and fast data processing around the world, is propelling the growth of the market. Furthermore, key market players are introducing label-free technology to provide simple methods for studying complex biological pathways and reduce the risk of drug failure caused by toxicity. These players are also investing in research and development (R&D) activities to develop new technologies in HTS. Besides this, they are launching a time-resolved Forster resonance energy transfer (TR-FRET) version of the transcreener assay for various enzymes. These innovations are projected to bolster the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global high-throughput screening market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on technology, products and services, applications, and end user.
Breakup by Technology:
- Ultra-High-Throughput Screening
- Cell-Based Assays
- Lab-on-a-Chip
- Label-Free Technology
Breakup by Products and Services:
- Instruments
- Reagents and Kits
- Services
Breakup by Applications:
- Target Identification and Validation
- Primary and Secondary Screening
- Toxicology Assessment
- Others
Breakup by End User:
- Pharmaceutical and Biotechnology Firms
- Academic and Government Institutes
- Contract Research Organizations
- Others
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Aurora Biomed Inc., Axxam S.p.A, Beckman Coulter Inc. (Danaher Corporation), Bio-RAD Laboratories Inc., Charles River Laboratories International Inc., Corning Incorporated, Luminex Corporation (DiaSorin), Perkinelmer Inc., Sygnature Discovery, Tecan Group Ltd. and Thermo Fisher Scientific.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Segment Coverage |
Technology, Products and Services, Applications, End User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Agilent Technologies Inc., Aurora Biomed Inc., Axxam S.p.A, Beckman Coulter Inc. (Danaher Corporation), Bio-RAD Laboratories Inc., Charles River Laboratories International Inc., Corning Incorporated, Luminex Corporation (DiaSorin), Perkinelmer Inc., Sygnature Discovery, Tecan Group Ltd. and Thermo Fisher Scientific. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global high-throughput screening market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global high-throughput screening market?
- What are the key regional markets?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the products and services?
- What is the breakup of the market based on the applications?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global high-throughput screening market and who are the key players?
- What is the degree of competition in the industry?